Yes, for most people, you have to stay on Ozempic (semaglutide) long-term, potentially indefinitely, to maintain weight loss, as weight regain is common after stopping due to the medication mimicking fullness hormones and the body's natural tendency to regain weight. While Ozempic is a diabetes drug, its effectiveness for weight management means it's often viewed as a chronic treatment, requiring ongoing use, much like managing blood pressure or diabetes, to keep weight off.
If you find that you're not losing weight on Ozempic or other GLP-1 medications, your metabolism, or how quickly your body burns calories, may be the cause. It's sometimes called the “Ozempic plateau,” but it can happen with any weight loss program.
While nothing is guaranteed, it is common to regain some weight after stopping Ozempic. A study found many people regain two-thirds or more of the weight they lost within a year of stopping the medication. Please remember, this isn't a failure of willpower.
If you don't have diabetes and aren't taking the medication for blood sugar control, you probably won't have to take Ozempic forever. You might take the drug until you reach your goal weight and a healthcare provider advises you to stop taking it.
But about half of people with obesity on this class of medications, called glucagon-like peptide agonists or GLP-1s, stop taking it within a year. Studies suggest that most people discontinue their use due to the high cost and adverse gastrointestinal side-effects.
The most common long-term side effects of Ozempic are stomach-related, including nausea, vomiting, and associated symptoms. If you experience gastrointestinal issues like these for more than a few weeks, contact your physician.
Potential Long-Term Ozempic Side Effects
Increased heart rate and heart palpitations. Changes in vision quality (often related to diabetic retinopathy) Gallstones and gallbladder disease. Pancreatitis (inflammation of the pancreas)
"Ozempic face" as a side effect of GLP-1 drugs
Those with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), pancreatitis, or gallbladder disease are not suitable candidates for Ozempic. In addition, this treatment is not intended for pregnant or breastfeeding women.
Will Ozempic or Wegovy reduce belly fat? The answer appears to be yes. That Novo Nordisk-funded study of almost 2,000 overweight or obese adults without diabetes also found their visceral fat — the type that accumulates in the belly — was reduced from baseline with semaglutide, along with their total fat mass.
The digestive effects of sugary drinks can be particularly uncomfortable: Increased nausea and vomiting - Sweet beverages can trigger or worsen the most common side effects of Ozempic. Exacerbated GI upset - Sugary drinks often intensify digestive discomfort already present from the medication.
Nevertheless, most people will notice a significant difference in their appearance after losing 20 pounds. One of the most noticeable changes is reduced body fat, which can lead to a slimmer appearance. Additionally, we can often identify that our clothes may feel looser and more comfortable.
Stopping semaglutide (Ozempic or Wegovy) too quickly can lead to rebound weight gain. But it doesn't have to. With the right plan, gradual dose reduction, and support from an experienced care team, it's possible to maintain your weight loss long-term.
"Ozempic hands" is a slang term for the visible changes in hands due to rapid fat loss from GLP-1 drugs like Ozempic, making them look thinner, bonier, and more aged with prominent veins, tendons, and thinner skin, as subcutaneous fat diminishes and skin doesn't fully contract quickly. It's not a formal diagnosis but a common cosmetic effect of significant weight loss, similar to "Ozempic face".
How long will it take to shed 30 lbs on Ozempic? On average, losing 30 pounds occurs within 5-6 months of sustained treatment.
'Ozempic legs' is an informal term describing visible changes in leg appearance—such as reduced fat volume, increased muscle and vein visibility, and looser skin—that some people experience during treatment with semaglutide (Ozempic) or similar GLP-1 receptor agonists.
Nothing in Ozempic leads to aging or sagging skin. While many people blame Ozempic for appearance changes, the real reason people look like they've rapidly aged after significant weight loss is simple.
Do not use Ozempic® if: you or any of your family have ever had MTC or if you have MEN 2. you are allergic to semaglutide or any of the ingredients in Ozempic®. See symptoms of serious allergic reaction in “What are the possible side effects of Ozempic®?”.
When you take Ozempic, it mimics GLP-1 and activates receptors in the brain, especially in areas like the hypothalamus. This leads to several neurological effects, including: Decreased hunger and fewer food cravings. Earlier feelings of fullness.
Rapid weight loss is a significant factor in the development of 'Ozempic Face. ' To minimize its impact, aim for a steady and gradual weight loss. This approach allows your skin more time to adjust and tighten naturally, reducing the risk of a gaunt appearance.
No, Ozempic hasn't been shown to affect lifespan, but no studies have directly measured its impact on lifespan.
Across Reddit, TikTok, and support groups, users are sharing experiences of emotional blunting, anxiety, and depressive episodes they didn't expect. Some describe feeling “flat” or “numb.” Others say they've lost interest in things they once enjoyed. And in more serious cases, a few have reported thoughts of self-harm.
During a January 29 appearance on The Howard Stern Show, Schumer elaborated on how while the weight loss results were impressive, Ozempic made her so sick that she felt like she was "shriveling away." “I lost 30 pounds so quick. I looked great, but I couldn't lift my head off the pillow.
The researchers found that people using it had an increased risk of gastrointestinal conditions (like nausea and vomiting), abdominal pain, low blood pressure and arthritis. Surprisingly, the researchers also uncovered an increased risk of uncommon, yet serious, pancreas and kidney conditions.